SAR of a series of inhaled A sub(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data

COPD is a major cause of mortality in the western world. A sub(2A) agonists are postulated to reduce the lung inflammation that causes COPD. The cardiovascular effects of A sub(2A) agonists dictate that a compound needs to be delivered by inhalation to be therapeutically useful. The pharmacological and pharmacokinetic SAR of a series of inhaled A sub(2A) agonists is described leading through to human pharmacokinetic data for a clinical candidate.